BRPI0815564B8 - anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met - Google Patents

anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met

Info

Publication number
BRPI0815564B8
BRPI0815564B8 BRPI0815564A BRPI0815564A BRPI0815564B8 BR PI0815564 B8 BRPI0815564 B8 BR PI0815564B8 BR PI0815564 A BRPI0815564 A BR PI0815564A BR PI0815564 A BRPI0815564 A BR PI0815564A BR PI0815564 B8 BRPI0815564 B8 BR PI0815564B8
Authority
BR
Brazil
Prior art keywords
met
antibody
antibodies
inhibit
underexpression
Prior art date
Application number
BRPI0815564A
Other languages
English (en)
Portuguese (pt)
Inventor
Goetsch Liliane
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815564(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0815564A2 publication Critical patent/BRPI0815564A2/pt
Publication of BRPI0815564B1 publication Critical patent/BRPI0815564B1/pt
Publication of BRPI0815564B8 publication Critical patent/BRPI0815564B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
BRPI0815564A 2007-07-12 2008-07-10 anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met BRPI0815564B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
EP07301231A EP2014681A1 (en) 2007-07-12 2007-07-12 Novel antibodies inhibiting c-met dimerization, and uses thereof
US2063908P 2008-01-11 2008-01-11
PCT/EP2008/059026 WO2009007427A2 (en) 2007-07-12 2008-07-10 Novel antibodies inhibiting c-met dimerization, and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0815564A2 BRPI0815564A2 (pt) 2015-02-18
BRPI0815564B1 BRPI0815564B1 (pt) 2020-01-21
BRPI0815564B8 true BRPI0815564B8 (pt) 2021-05-25

Family

ID=38871713

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815564A BRPI0815564B8 (pt) 2007-07-12 2008-07-10 anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met

Country Status (35)

Country Link
US (6) US8329173B2 (OSRAM)
EP (6) EP2014681A1 (OSRAM)
JP (4) JP5562844B2 (OSRAM)
KR (4) KR101625234B1 (OSRAM)
CN (4) CN103509112B (OSRAM)
AR (4) AR067517A1 (OSRAM)
AU (1) AU2008274171B2 (OSRAM)
BR (1) BRPI0815564B8 (OSRAM)
CA (4) CA2888691C (OSRAM)
CL (1) CL2008002015A1 (OSRAM)
CO (1) CO6170364A2 (OSRAM)
CY (1) CY1116608T1 (OSRAM)
DK (1) DK2188312T3 (OSRAM)
ES (5) ES2693542T3 (OSRAM)
HR (1) HRP20150887T1 (OSRAM)
HU (1) HUE026026T2 (OSRAM)
IL (5) IL203114A (OSRAM)
MA (1) MA31977B1 (OSRAM)
ME (1) ME02341B (OSRAM)
MX (3) MX345391B (OSRAM)
MY (1) MY158756A (OSRAM)
NZ (4) NZ599958A (OSRAM)
PA (1) PA8789201A1 (OSRAM)
PH (3) PH12018502039A1 (OSRAM)
PL (1) PL2188312T3 (OSRAM)
PT (1) PT2188312E (OSRAM)
RS (1) RS54197B1 (OSRAM)
RU (1) RU2552161C2 (OSRAM)
SA (1) SA08290423B1 (OSRAM)
SG (1) SG183015A1 (OSRAM)
SI (1) SI2188312T1 (OSRAM)
TN (1) TN2010000016A1 (OSRAM)
TW (4) TWI592427B (OSRAM)
WO (1) WO2009007427A2 (OSRAM)
ZA (1) ZA201000966B (OSRAM)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
JP5497887B2 (ja) 2009-04-07 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−２／抗ｃ−Ｍｅｔ抗体
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
EP3511342B1 (en) * 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
EP2808344A1 (en) * 2010-06-01 2014-12-03 Monash University Antibodies directed to the receptor tyrosine kinase c-Met
EP2402370A1 (en) 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
RU2013114783A (ru) * 2010-09-03 2014-10-10 Академиа Синика Anti-с-мет антитела и способы их применения
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
EP2853542A1 (en) 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP3466972A1 (en) 2011-06-23 2019-04-10 Ablynx NV Serum albumin binding proteins
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN103889451B (zh) * 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2863946A4 (en) 2012-06-21 2016-04-13 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102200274B1 (ko) 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
EP3221468B1 (en) * 2014-11-20 2020-03-25 Stichting Katholieke Universiteit A novel auto-active and intracellular mutant of met
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
EP3233910B1 (en) 2014-12-19 2019-12-11 Ablynx N.V. Cysteine linked nanobody dimers
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
JP6929786B2 (ja) 2015-04-02 2021-09-01 アブリンクス エン．ヴェー． 強力な抗ｈｉｖ活性を有する二重特異性ｃｘｃｒ４−ｃｄ４ポリペプチド
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
WO2017062496A2 (en) * 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
EP3371223B1 (en) 2015-11-03 2021-03-10 Merck Patent GmbH Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
MX2018014175A (es) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
AU2017292752B2 (en) * 2016-07-06 2023-07-27 Celgene Corporation Antibodies with low immunogenicity and uses thereof
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2019018538A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. RECOMBINANT ANTIBODIES BINDING TO CD123
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
WO2019117691A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
US20210051929A1 (en) * 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
CN115605491A (zh) 2019-04-05 2023-01-13 刘扶东（Us） 抗唾液酸酶的糖类、其制造方法及用途
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN116075315B (zh) 2020-05-08 2025-12-19 周美吟 嵌合流感疫苗
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN116783220A (zh) * 2020-12-16 2023-09-19 武汉友芝友生物制药股份有限公司 抗bcma抗体及其制备方法和应用
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
AU2022253888A1 (en) 2021-04-06 2023-09-28 AbbVie Manufacturing Management Unlimited Company Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
US12257298B2 (en) 2021-04-12 2025-03-25 Academia Sinica Coronavirus vaccine
UY39743A (es) 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN120787235A (zh) * 2021-12-27 2025-10-14 周美吟 Sars-cov-2棘蛋白特异性抗体及其用途
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE69800716T2 (de) * 1997-04-14 2001-09-20 Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1485130A4 (en) * 2002-02-21 2006-11-22 Univ Duke REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
CA2516236A1 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
KR101412271B1 (ko) * 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
KR101363120B1 (ko) * 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
RS54984B1 (sr) 2005-07-18 2016-11-30 Amgen Inc Humana anti-b7rp1 neutrališuća antitela
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US8388958B2 (en) 2006-02-06 2013-03-05 Metheresis Translational Research Sa Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
CN103183738B (zh) 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody

Also Published As

Publication number Publication date
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
CA2982484C (en) 2021-06-01
IL223106A0 (en) 2012-12-31
CN103183739B (zh) 2016-08-17
CY1116608T1 (el) 2017-03-15
MA31977B1 (fr) 2011-01-03
NZ613716A (en) 2015-01-30
PA8789201A1 (es) 2009-08-26
EP2535357B1 (en) 2018-08-08
SI2188312T1 (sl) 2015-09-30
AR109535A2 (es) 2018-12-19
US20130280257A1 (en) 2013-10-24
RU2552161C2 (ru) 2015-06-10
US20130273060A1 (en) 2013-10-17
TW201437231A (zh) 2014-10-01
ZA201000966B (en) 2011-02-23
TWI602830B (zh) 2017-10-21
AR067517A1 (es) 2009-10-14
CA2981821C (en) 2020-07-28
CN103183739A (zh) 2013-07-03
IL203114A (en) 2015-03-31
KR101701685B1 (ko) 2017-02-01
US20130272957A1 (en) 2013-10-17
EP2188312B1 (en) 2015-05-27
AU2008274171A1 (en) 2009-01-15
MX353449B (es) 2018-01-08
WO2009007427A2 (en) 2009-01-15
IL223108B (en) 2019-06-30
SA08290423B1 (ar) 2013-12-23
HUE026026T2 (en) 2016-05-30
TW201605891A (zh) 2016-02-16
CO6170364A2 (es) 2010-06-18
EP2188312A2 (en) 2010-05-26
RU2010104633A (ru) 2011-08-20
US8871909B2 (en) 2014-10-28
PL2188312T3 (pl) 2016-01-29
EP2535357A1 (en) 2012-12-19
JP2014113154A (ja) 2014-06-26
JP5562844B2 (ja) 2014-07-30
JP2014113153A (ja) 2014-06-26
IL223106B (en) 2020-06-30
KR101701686B1 (ko) 2017-02-01
US20140010818A1 (en) 2014-01-09
EP2415784A1 (en) 2012-02-08
ES2678495T3 (es) 2018-08-13
PH12018502038A1 (en) 2019-08-19
TWI592427B (zh) 2017-07-21
BRPI0815564B1 (pt) 2020-01-21
KR20160019974A (ko) 2016-02-22
HRP20150887T1 (hr) 2015-09-25
IL223109A0 (en) 2012-12-31
KR20100044212A (ko) 2010-04-29
EP2535356B1 (en) 2018-06-13
DK2188312T3 (en) 2015-08-03
SG183015A1 (en) 2012-08-30
NZ599958A (en) 2013-11-29
CA2982484A1 (en) 2009-01-15
EP2014681A1 (en) 2009-01-14
TN2010000016A1 (en) 2011-09-26
ME02341B (me) 2015-12-31
WO2009007427A3 (en) 2009-04-09
IL223105A0 (en) 2012-12-31
HK1193619A1 (zh) 2014-09-26
AU2008274171B2 (en) 2014-02-27
CA2888691C (en) 2023-01-03
CL2008002015A1 (es) 2008-11-21
TWI549965B (zh) 2016-09-21
MY158756A (en) 2016-11-15
KR101719084B1 (ko) 2017-03-22
AR109660A2 (es) 2019-01-09
PH12018502039A1 (en) 2019-08-19
PT2188312E (pt) 2015-10-05
ES2686693T3 (es) 2018-10-19
CN101981054A (zh) 2011-02-23
NZ583041A (en) 2012-06-29
TW200911828A (en) 2009-03-16
HK1149024A1 (en) 2011-09-23
IL223105B (en) 2020-02-27
JP2010532982A (ja) 2010-10-21
JP5889925B2 (ja) 2016-03-22
CN101981054B (zh) 2015-04-15
HK1193620A1 (zh) 2014-09-26
US8329173B2 (en) 2012-12-11
CA2888691A1 (en) 2009-01-15
EP2415784B1 (en) 2018-06-13
US20100115639A1 (en) 2010-05-06
MX341012B (es) 2016-08-03
PH12018502040A1 (en) 2019-08-19
KR20150070451A (ko) 2015-06-24
KR101625234B1 (ko) 2016-05-30
IL223108A0 (en) 2012-12-31
US9107907B2 (en) 2015-08-18
EP2535356A1 (en) 2012-12-19
CA2694418A1 (en) 2009-01-15
CA2981821A1 (en) 2009-01-15
TW201605892A (zh) 2016-02-16
BRPI0815564A2 (pt) 2015-02-18
EP2415785A1 (en) 2012-02-08
US20150252114A1 (en) 2015-09-10
TWI602829B (zh) 2017-10-21
ES2693542T3 (es) 2018-12-12
EP2415785B1 (en) 2018-04-25
IL223109B (en) 2019-06-30
JP5889924B2 (ja) 2016-03-22
US8889832B2 (en) 2014-11-18
CN103509113B (zh) 2015-10-21
RS54197B1 (sr) 2015-12-31
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
JP5889923B2 (ja) 2016-03-22
CN103509112A (zh) 2014-01-15
JP2014113155A (ja) 2014-06-26
US8871910B2 (en) 2014-10-28
CN103509112B (zh) 2015-10-21
CN103509113A (zh) 2014-01-15
CA2694418C (en) 2018-03-27
AR109659A2 (es) 2019-01-09
MX345391B (es) 2017-01-27

Similar Documents

Publication Publication Date Title
BRPI0815564B8 (pt) anticorpos que inibem a dimerização de c-met e usos dos mesmos, hibridoma de murino, anticorpo, ácido nucleico isolado, vetor, método para produção de anticorpo, composição, uso e método de diagnóstico in vitro de enfermidades induzidas por uma superexpressão ou subexpressão do receptor de c-met
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
FI3036258T3 (fi) Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BR112022006001A2 (pt) Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
BR112014007721A2 (pt) processos para preparar compostos úteis como inibidores de atr quinase
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
BRPI0506726B8 (pt) anticorpo monoclonal específico para m-csf e usos deste
BRPI0923359B8 (pt) molécula de anticorpo anti-igf, método para a produção da mesma, molécula de dna, vetor de expressão, e composição farmacêutica e método in vitro para inibir a ligação do igf-1 e do igf-2 ao receptor de igf-1 e ao receptor de insulina ir-a
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
BR112012016992A2 (pt) "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
BR112014008775A2 (pt) camundongo de cadeia pesada de imunoglobulina restrita
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BRPI0606891A2 (pt) anticorpos dr5 e usos dos mesmos
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
BR112012030318A2 (pt) composto específicos de anti-cd160 para o tratamento de transtornos oculares com base em neoangiogênese
BR112012014984A2 (pt) anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF